Singapore has approved the use of the Pfizer-BioNTech COVID-19 vaccine for children aged 12 to 15 years, officials announced on May 18.
“The Pfizer-BioNTech COVID-19 vaccine demonstrated high efficacy and safety for this age group of 12 to 15 years old, which is consistent with what we have observed for the adult population,” Health Minister Ong Ye Kung said at a press conference.
“Its safety profile is also consistent with the known safety profile in the adult population and the standards set for other registered vaccines used in the immunization against other diseases,” the health ministry also said in a statement.
According to the Health Sciences Authority, the body that authorized the use of the vaccine, the efficacy was based on the ongoing Phase 3 clinical trial with over 2,000 participants aged between 12 and 15 years.
The health ministry also stated that it will work with the education ministry on the vaccination program for the age group.
The Pfizer-BioNTech COVID-19 vaccine is the first vaccine to be approved for the age group in Singapore.
The authorization comes after the approval of the same vaccine for the same age group in Canada, the United States, and the United Arab Emirates.
According to data from the health ministry, Singapore has administered 3,407,068 doses.
Singapore also reported 27 new local cases and 11 new imported cases on May 18, bringing the total to 61,651 cases.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.